Aurobindo Pharma falls after US FDA flags Apitoria unit
In short
Aurobindo Pharma shares fell nearly 2% after the US FDA issued a Form 483 for its Apitoria Pharma unit.
The update came with a VAI classification for the manufacturing facility. The market reaction ended the stock’s 12-day winning streak.
What the reporting says
Aurobindo Pharma shares fell nearly 2% after the US FDA issued a Form 483 with a VAI classification for its subsidiary Apitoria Pharma Private Limited’s manufacturing facility, according to a market summary. The inspection update ended the company’s 12-day winning streak in trading. The report links the decline to the regulatory observation at the API unit.
Why it matters
The market moved against Aurobindo Pharma after the US FDA issued a Form 483 for the company’s subsidiary Apitoria Pharma Private Limited, with a VAI classification for the manufacturing facility. The update weighed on the stock and snapped a 12-day winning streak, according to the summary. The event is a regulatory inspection update affecting a pharma manufacturing asset.